These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3700040)

  • 1. Phase II trial of acivicin in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.
    McGuire WP; Blessing JA; DiSaia PJ; Buchsbaum HJ
    Invest New Drugs; 1986; 4(1):49-52. PubMed ID: 3700040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical trial of acivicin in advanced breast cancer: an Eastern Cooperative Oncology Group Study.
    Willson JK; Knuiman MW; Skeel RT; Wolter JM; Pandya KJ; Falkson G; Chang YC
    Cancer Treat Rep; 1986 Oct; 70(10):1237-8. PubMed ID: 3530452
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II study of acivicin in colorectal carcinoma: a National Cancer Institute of Canada study.
    Maroun JA; Fields AL; Pater JL; Stewart DJ; Cripps C; Eisenhauer E
    Cancer Treat Rep; 1984 Sep; 68(9):1121-3. PubMed ID: 6478451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of acivicin in lung cancer: a Southeastern Cancer Study Group Trial.
    Kramer BS; Birch R; Greco A; Prestridge K; Johnson R
    Cancer Treat Rep; 1986 Aug; 70(8):1031-2. PubMed ID: 3524833
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II trial of continuous drug infusions in advanced ovarian carcinoma: acivicin versus vinblastine.
    Earhart RH; Khandekar JD; Faraggi D; Schinella RA; Davis TE
    Invest New Drugs; 1989 Jul; 7(2-3):255-60. PubMed ID: 2793383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of acivicin in advanced breast carcinoma: a Cancer and Leukemia Group B Study.
    Booth BW; Korzun AH; Weiss RB; Ellison RR; Budman D; Khojasteh A; Wood W
    Cancer Treat Rep; 1986 Oct; 70(10):1247-8. PubMed ID: 3530455
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II study of acivicin in non-small cell lung cancer: a National Cancer Institute of Canada Study.
    Maroun JA; Maksymiuk A; Eisenhauer E; Stewart DJ; Young V; Pater J
    Cancer Treat Rep; 1986 Nov; 70(11):1327-8. PubMed ID: 3021326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of acivicin in patients with advanced colorectal carcinoma.
    Adolphson CC; Ajani JA; Stroehlein JR; Barlogie B; Bodey GP; Korinek J; Bedikian AY
    Am J Clin Oncol; 1986 Jun; 9(3):189-91. PubMed ID: 3728371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I-II trial of acivicin in adult acute leukemia.
    Powell BL; Craig JB; Capizzi RL; Richards F
    Invest New Drugs; 1988 Apr; 6(1):41-4. PubMed ID: 3165971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of acivicin as a 72-hr continuous infusion in patients with untreated colorectal cancer. A National Cancer Institute of Canada Clinical Trials Group Study.
    Eisenhauer EA; Maroun JA; Fields AL; Walde PL
    Invest New Drugs; 1987 Dec; 5(4):375-8. PubMed ID: 3436743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of acivicin in patients with advanced cancer.
    Sridhar KS; Ohnuma T; Chahinian AP; Holland JF
    Cancer Treat Rep; 1983; 67(7-8):701-3. PubMed ID: 6871885
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
    McGuire WP; Blessing JA; Berman ML
    Invest New Drugs; 1989 Nov; 7(4):333-6. PubMed ID: 2557300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of acivicin in malignant mesothelioma.
    Falkson G; Vorobiof DA; Simson IW; Borden EC
    Cancer Treat Rep; 1987 May; 71(5):545-6. PubMed ID: 3567981
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomized phase II study of acivicin and 4'deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study.
    Falkson G; Cnaan A; Simson IW; Dayal Y; Falkson H; Smith TJ; Haller DG
    Am J Clin Oncol; 1990 Dec; 13(6):510-5. PubMed ID: 2173394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gynecologic Oncology Group experience with ifosfamide.
    Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):6-10. PubMed ID: 2159188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of acivicin in advanced metastatic breast cancer.
    Fleishman G; Yap HY; Murphy WK; Bodey G
    Cancer Treat Rep; 1983 Sep; 67(9):843-4. PubMed ID: 6883364
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acivicin in 1985.
    Earhart RH; Neil GL
    Adv Enzyme Regul; 1985; 24():179-205. PubMed ID: 3915184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary. A Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; Arseneau JC; Homesley HD
    Am J Clin Oncol; 1984 Jun; 7(3):261-3. PubMed ID: 6547268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.